LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

Strona główna・Stock List・Bristol-Myers Squibb Co.

Bristol-Myers Squibb Co.

Closed

SectorHealthcare

54.89 0.96

Buy Sell

Overview

Share price change

24h

Current

Min

54.31

Max

55.05

Key metrics
By Trading Economics
Income	1.6B 2.7B
Sales	-1B 11B
P/E Sector Avg	15.392 49.888
EPS	1.31
Dividend yield	4.37
Profit margin	23.309
Employees	32,500
EBITDA	1.5B 3.7B

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+16.25% upside

Dividends
By Dow Jones
Dividend yield Sector Avg	4.37% 2.38%
Next Earnings	30 lip 2026
Next Dividend date	31 lip 2026
Next Ex Dividend date	2 lip 2026

Market Stats
By TradingEconomics
Market Cap	-5.8B 112B
Previous open	53.93
Previous close	54.89

News Sentiment

By Acuity

43%

57%

132 / 344 Ranking in Healthcare

Bristol-Myers Squibb Co. Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

3 cze 2026, 13:08 UTC

Earnings

Arcus to Supply Experimental Kidney Cancer Drug for Myers Squibb Trial

12 maj 2026, 06:42 UTC

Major Market Movers

Bristol Myers Squibb and China's Hengrui Pharma Forge Tie-Up

30 kwi 2026, 11:14 UTC

Earnings

Bristol Myers Squibb Logs Higher 1Q Sales Driven by Growth Portfolio

29 maj 2026, 08:15 UTC

Market Talk

Earnings

Bayer's Key Pharma Products Face Competitive Risk -- Market Talk

5 maj 2026, 18:12 UTC

Earnings

BioNTech to Slash 22% of Workforce as Losses Widen. The Stock Falls. -- Barrons.com

5 maj 2026, 13:54 UTC

Earnings

BioNTech to Slash 25% of Workforce as Losses Widen. The Stock Falls. -- Barrons.com

30 kwi 2026, 10:59 UTC

Earnings

Bristol Myers Squibb: Continue to See Total Worldwide Eliquis Revenue Increasing 10%-15% in 2026 Vs Yr-Ago >BMY

30 kwi 2026, 10:59 UTC

Earnings

Bristol Myers Squibb: 2026 Guidance Excludes Impact of Any Potential Future Strategic Acquisitions, Divestitures and Impact of Future Acquired IPRD Charges and Licensing Income >BMY

30 kwi 2026, 10:59 UTC

Earnings

Bristol Myers Squibb: Reaffirming 2026 Financial Guidance With Total Revenue and Diluted EPS Trending Toward Upper End of Ranges >BMY

30 kwi 2026, 10:59 UTC

Earnings

Bristol Myers Squibb Backs 2026 Rev $46B-$47.5B >BMY

30 kwi 2026, 10:59 UTC

Earnings

Bristol Myers Squibb 1Q International Revenue Rose 11% to $3.7B >BMY

30 kwi 2026, 10:59 UTC

Earnings

Bristol Myers Squibb: 1Q Results Reflecting Sustained Momentum Across Our Growth Portfolio and Disciplined Execution Throughout the Business >BMY

30 kwi 2026, 10:59 UTC

Earnings

Bristol Myers Squibb 1Q U.S. Revenue Fell 1% to $7.79B >BMY

30 kwi 2026, 10:59 UTC

Earnings

Bristol Myers Squibb 1Q Rev $11.49B >BMY

30 kwi 2026, 10:59 UTC

Earnings

Bristol Myers Squibb: In Legacy Portfolio, Demand Increased for Eliquis in 1Q, Which Was More Than Offset by Expected Continued Generic Impacts Across Remainder of Portfolio >BMY

30 kwi 2026, 10:59 UTC

Earnings

Bristol Myers Squibb: 1Q Growth Portfolio Revenue Increase Primarily Driven by Reblozyl, Camzyos and Breyanzi >BMY

30 kwi 2026, 10:59 UTC

Earnings

Bristol Myers Squibb 1Q Eliquis Revenue Rose 16% to $4.14B >BMY

30 kwi 2026, 10:59 UTC

Earnings

Bristol Myers Squibb Backs 2026 Adj EPS $6.05-Adj EPS $6.35 >BMY

30 kwi 2026, 10:59 UTC

Earnings

Bristol Myers Squibb 1Q Adjusted Gross Margin 70.3% >BMY

30 kwi 2026, 10:59 UTC

Earnings

Bristol Myers Squibb 1Q Growth Portfolio Revenue Rose 12% to $6.23B >BMY

30 kwi 2026, 10:59 UTC

Earnings

Bristol Myers Squibb 1Q EPS $1.31 >BMY

30 kwi 2026, 10:59 UTC

Earnings

Bristol Myers Squibb 1Q Legacy Portfolio Rev Fell 6% to $5.28B >BMY

30 kwi 2026, 10:59 UTC

Earnings

Bristol Myers Squibb 1Q Adj EPS $1.58 >BMY

30 kwi 2026, 10:59 UTC

Earnings

Bristol Myers Squibb: Latest 1Q Includes Net Impact of Loss of 3c/Shr Due to Acquired IPRD Charges and Licensing Income >BMY

30 kwi 2026, 10:59 UTC

Earnings

Bristol Myers Squibb 1Q Gross Margin 70.2% >BMY

14 kwi 2026, 14:13 UTC

Earnings

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14 kwi 2026, 12:57 UTC

Earnings

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14 kwi 2026, 11:19 UTC

Earnings

Johnson & Johnson Beats Earnings Estimates. Cancer Treatments Help Drive the Quarter. -- Barrons.com

14 kwi 2026, 10:34 UTC

Earnings

Johnson & Johnson Stock Rises on Earnings Beat. These Segments Boosted the Quarter. -- Barrons.com

13 kwi 2026, 21:23 UTC

Earnings

Johnson & Johnson Earnings: Oncology Powers Growth, but Talc Lawsuits Persist -- Barrons.com

Peer Comparison

Price change

Bristol-Myers Squibb Co. Forecast

Price Target

By TipRanks

16.25% upside

12 Months Forecast

Average 63.31 USD 16.25%

High 75 USD

Low 40 USD

Based on 20 Wall Street analysts offering 12 month price targets forBristol-Myers Squibb Co. - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

20 ratings

Buy

Hold

Sell

Based on 20 analysts giving stock ratings to Bristol-Myers Squibb Co. - Dist in the past 3 months.

Sentiment

By Acuity

132 / 344 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.